biostudies-literatureLin NUNCI NIH HHS2623-31https://www.ebi.ac.uk/biostudies/studies/S-EPMC4534525biostudies-literatureUnknown33(24)<h4>Purpose</h4>Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC). We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes.<h4>Patients and methods</h4>Two cohorts were enrolled (cohort 1: no prior trastuzumab for MBC and ≥ 1 year from adjuvant trastuzumab, if given; cohort 2: one to two lines of chemotherapy including trastuzumab for MBC and/or recurrence < 1 year from adjuvant trastuzumab). The primary end point was objective response rate by RECIST v1.0; secondary end points included clinical benefit rate (complete response plus partiaJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).PMC4534525P50 CA089393CA089393CA089393-10S1Hobday TJNanda RFalkson CIDees ECArteaga CLVan den Abbeele ADYap JTRimawi MFWiner EPMayer IABarry WTRyabin NGuo HNajita JSRichardson ALLin NUWolff ACKrop IEfalsePhase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).<h4>Purpose</h4>Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC). We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes.<h4>Patients and methods</h4>Two cohorts were enrolled (cohort 1: no prior trastuzumab for MBC and ≥ 1 year from adjuvant trastuzumab, if given; cohort 2: one to two lines of chemotherapy including trastuzumab for MBC and/or recurrence < 1 year from adjuvant trastuzumab). The primary end point was objective response rate by RECIST v1.0; secondary end points included clinical benefit rate (complete response plus partia2015-01-01T00:00:00Z2015 Aug2025-04-03T22:29:25.541Z2019-03-27T01:56:40ZS-EPMC45345252616961510.1200/jco.2014.60.035310.1200/JCO.2014.60.0353